Two-tooth endoscopic clip to help remove and close stomach GISTs
Official title: Efficacy and Safety of a Novel Two-Tooth Clip-Assisted ESD and EFTR of GIST: A Single-Center, Prospective, Open-Label, Randomized Controlled Study
Run by Affiliated Hospital to Academy of Military Medical Sciences · NCT07581977 · Data updated 2026-11-12
Doctors will try a new two-tooth endoscopic clip used with a clip-and-line traction method during ESD and EFTR to see if it makes removing and closing gastric GISTs (2–5 cm) faster and safer for adults.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Affiliated Hospital to Academy of Military Medical Sciences Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | April 24, 2026 |
| Main results expected | April 24, 2027 |
| Study ends | July 1, 2027 |
| Registry record updated | May 22, 2026 |
| Trial ID | NCT07581977 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–85 years old with gastric GISTs 2–5 cm who are appropriate candidates for endoscopic resection and can safely pause/bridge anticoagulation are the intended participants.
✕Probably not a fit
Patients with clear deep submucosal invasion or distant metastases, severe coagulopathy or organ failure, pregnancy or lactation, or prior significant fibrosis at the lesion site are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective randomized trial comparing a novel two-tooth endoscopic clip used in a clip-with-line traction technique versus conventional ESD methods for adults with gastric GISTs 2–5 cm. In the procedure the clip will first be anchored to the lesion and a dental line used to provide counter-traction to expose the submucosal dissection plane, and after resection the same clip system will be used for continuous circumferential defect closure. Primary outcomes include measures of submucosal dissection efficiency (procedure time and en-bloc resection completeness) and safety, while secondary outcomes focus on closure performance for full-thickness or mucosal defects. All procedures are performed by experienced endoscopists following standard inclusion and exclusion criteria.
Why it matters
Potential benefit: If successful, the device could shorten procedure time, improve visualization for complete resection, reduce bleeding and perforation risk, and simplify defect closure.
How similar studies have gone: Clip-with-line traction methods and endoscopic closure techniques have demonstrated benefit in prior work, but the two-tooth clip geometry is a novel device with limited prior clinical data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 and ≤ 85 years. * Patients diagnosed with gastric gastrointestinal lesions clinically indicated for ESD or EFTR. * Lesion size between 2 cm and 5 cm in diameter. * Willing and able to provide written informed consent. Exclusion Criteria: * Lesions with clear evidence of deep submucosal invasion or distant metastasis precluding curative endoscopic resection. * Severe coagulation dysfunction (international normalized ratio \>2.0, platelet count \<50,000/µL) or ongoing use of dual antiplatelet therapy/anticoagulants that cannot be appropriately bridged or discontinued per guidelines. * Severe organ failure (cardiac, renal, hepatic, or respiratory) rendering the patient unsuitable for prolonged sedation or general anesthesia. * Pregnancy or lactation. * Prior surgical or endoscopic intervention at the target lesion site that results in significant fibrosis.
Where it's running
-
The Fifth Medical Center of Chinese PLA General Hospital
Beijing, China Recruiting
Study contacts
- Principal investigator: Yan Liu, M.D.,Ph.D. — Beijing 302 Hospital
- Study coordinator: Min Min, M.D., Ph.D.
- Email: minmin823@sina.com
- Phone: +86-010-66947473
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GIST Patient Registry for real-world insights
This registry collects medical information from people with GIST to see how the disease behaves in real life and to help improve care.
-
Regorafenib plus envafolimab versus physician's choice for metastatic GIST with KIT exon 17 mutation
This study will test whether combining regorafenib with the immune drug envafolimab helps people with metastatic GIST who have KIT exon 17 mutations and have stopped responding to standard treatments.
-
KQB198 plus imatinib for first-line advanced or metastatic GIST
This Phase 2 test will see if adding the experimental drug KQB198 to imatinib helps people with advanced or metastatic GIST who are starting first-line treatment.
-
NB003 for Advanced GIST: testing a new therapy vs regorafenib in adults
This trial tests NB003 in adults with advanced GI stromal tumors who have progressed on or cannot tolerate imatinib and sunitinib, comparing NB003 to regorafenib in different lines of therapy.
-
Evaluation of a new robotic surgical system for major gastrointestinal and urologic surgeries
This study is testing a new robotic surgery system to see if it can safely and effectively help patients with major gastrointestinal and urologic conditions like colorectal and prostate cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.